Transcenta is a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacturing.
Transcenta is competitive in new biologics R&D and manufacture.
Our proprietary Immune Tolerance Breaking Technology is capable of generating antibodies with diverse epitopes. Multiple partnerships on antibody discovery and co-development has been achieved based on this technology.
With our flexible manufacturing facility, we are able to accelerate product development and improve product quality control while significantly reducing the cost of production.
As of 2019, Transcenta has secured approximately USD 137 million from well-known investors including Lilly Asia Ventures, ARCH Venture Partners, Temasek, Sequoia Capital, Tengyue Partners, Taikang and Hillhouse Capital.
Contact
Address: Room 501, Building B6, 218 Xinghu Street, Suzhou Industrial Park (SIP) bioBAY, Suzhou, China
Website: http://www.transcenta.com/
Transcenta’s Xueming Qian outlines the new company’s origins, the space it seeks to fill within the highly competitive Chinese oncology market, and where Chinese biotech stands globally in 2019. …
Transcenta’s Xueming Qian outlines the new company’s origins, the space it seeks to fill within the highly competitive Chinese oncology market, and where Chinese biotech stands globally in 2019. …
See our Cookie Privacy Policy Here
